← boardnext 2029-06
IKT
Inhibikase Therapeuticsdistress 4/10 · elevated risk$2.19+1%today-2% from 52w high
Lead: Pulmonary Arterial Hypertension · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$170M
Runway
4.8 yrs
Shares 1y
+77%
Price & events
+21.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.9%
1D
+9.0%
1W
+17.1%
1M
+13.5%
3M
+25.9%
6M
+10.6%
1Y
+40.4%
2Y
-85.0%
5Y
-94.8%
All
Overview
- Market Cap
- $289.15M
- Volume
- 98.60K
- 52 Week Range
- $1.41 – $2.23
- Total Shares
- 132.03M
- Float Shares
- 61.88M
- Short %
- 23.66%
- % Held by Insiders
- 5.40%
- % Held by Institutions
- 78.58%
- RVOL
- 0.10x
- Beta
- 0.94
Pipeline stages · 1 programs
IKT-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
Catalyst news & presentations · 10
- 4Q26Guided 70%readoutPhase 2IkT-001Pro · Phase 2 top line resultsSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- April 7, 2026trial initiationsecondaryPhase 3IKT-001 · First patient enrolled in IMPROVE-PAH global Phase 3 studySEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 3IKT-001 · initiate global pivotal Phase 3 study IMPROVE-PAH in PAHSEC 8-K
- second half of 2025trial initiationsecondaryPhase 2IKT-001 · Initiation of Phase 2b IMPROVE-PAH studySEC 8-K
- 2 2025trial initiationsecondaryPhase 3risvodetinib · Phase 3 entry anticipatedSEC 8-K
- 2025-02-21partnershipMerger with CorHepta Pharmaceuticals, Inc.SEC 8-K
- 2025-01-29trial discontinuedrisvodetinib · Company paused further development of risvodetinib to focus on IkT-001Pro.SEC 8-K
- November, 2024readoutPhase 2risvodetinib · Phase 2 resultsSEC 8-K
- 2024-09-09fda agreementIkT-001Pro · FDA accepted IND and issued Study May Proceed letter for Phase 2 PAH studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+174% upside) · 9 analysts
- 2026-06-10OppenheimerOutperform
- 2026-03-04Ladenburg ThalmannBuy
- 2026-01-21B of A SecuritiesBuy
- 2025-12-17Freedom BrokerBuy
- 2025-12-11Cantor FitzgeraldOverweight
- 2025-03-28HC Wainwright & Co.Neutral
Competitors — Pulmonary Arterial Hypertension
Recent news
- 2026-07-23Inhibikase Gains FDA Orphan Drug Status for IKT-001 - TipRanks
- 2026-07-23Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation from FDA - GuruFocus
- 2026-07-23Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - The Manila Times
- 2026-07-23Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
- 2026-07-20Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
- 2026-07-19Inhibikase sells $50M of common stock to RA Capital - MSN
- 2026-07-18RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
- 2026-07-18Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.